These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24454763)

  • 1. Inhibition of c-Kit is not required for reversal of hyperglycemia by imatinib in NOD mice.
    Lau J; Zhou Q; Sutton SE; Herman AE; Schmedt C; Glynne R
    PLoS One; 2014; 9(1):e84900. PubMed ID: 24454763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
    Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
    Tamborini E; Bonadiman L; Greco A; Albertini V; Negri T; Gronchi A; Bertulli R; Colecchia M; Casali PG; Pierotti MA; Pilotti S
    Gastroenterology; 2004 Jul; 127(1):294-9. PubMed ID: 15236194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.
    Louvet C; Szot GL; Lang J; Lee MR; Martinier N; Bollag G; Zhu S; Weiss A; Bluestone JA
    Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18895-900. PubMed ID: 19015530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
    Sakurama K; Noma K; Takaoka M; Tomono Y; Watanabe N; Hatakeyama S; Ohmori O; Hirota S; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Tanaka N; Naomoto Y
    Mol Cancer Ther; 2009 Jan; 8(1):127-34. PubMed ID: 19139121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.
    Bosbach B; Deshpande S; Rossi F; Shieh JH; Sommer G; de Stanchina E; Veach DR; Scandura JM; Manova-Todorova K; Moore MA; Antonescu CR; Besmer P
    Proc Natl Acad Sci U S A; 2012 Aug; 109(34):E2276-83. PubMed ID: 22652566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.
    Pirson L; Baron F; Meuris N; Giet O; Castermans E; Greimers R; Di Stefano I; Gothot A; Beguin Y
    Stem Cells; 2006 Jul; 24(7):1814-21. PubMed ID: 16614006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
    Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
    Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
    Bardsley MR; Horváth VJ; Asuzu DT; Lorincz A; Redelman D; Hayashi Y; Popko LN; Young DL; Lomberk GA; Urrutia RA; Farrugia G; Rubin BP; Ordog T
    Gastroenterology; 2010 Sep; 139(3):942-52. PubMed ID: 20621681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.
    Wang CM; Huang K; Zhou Y; Du CY; Ye YW; Fu H; Zhou XY; Shi YQ
    J Cancer Res Clin Oncol; 2010 Jul; 136(7):1065-71. PubMed ID: 20043176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase.
    Dybko J; Haus O; Jazwiec B; Urbaniak J; Wozniak M; Kaczmar-Dybko A; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
    Acta Haematol; 2014; 132(2):166-71. PubMed ID: 24577437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice.
    Kamenz T; Caca K; Blüthner T; Tannapfel A; Mössner J; Wiedmann M
    World J Gastroenterol; 2006 Mar; 12(10):1583-90. PubMed ID: 16570351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
    Growney JD; Clark JJ; Adelsperger J; Stone R; Fabbro D; Griffin JD; Gilliland DG
    Blood; 2005 Jul; 106(2):721-4. PubMed ID: 15790786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
    Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
    Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.